Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is developing a platform of compounds with anti-fibrotic, anti-inflammatory, anti-infective and anti-oxidant activity. The Company develops a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. The platform consists of approximately 180 compounds. The Company's lead compound, AEOL 10150 (10150), is developed for the treatment of lung fibrosis, including idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The Company is also developing 10150 for use in combination with radiation therapy for cancer as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control. 10150 is also being developed as a medical counter measures (MCM) for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas and phosgene gas, and nerve agents, such as sarin gas and soman gas.